Cytokine expression and regulation of human plasma cells: disappearance of interleukin‐10 and persistence of transforming growth factor‐β<sub>1</sub>

Matthes, Thomas; Werner‐Favre, Christiane; Zubler, Rudolf H.

doi:10.1002/eji.1830250230

Cited by 22 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar data were presented by Ahmed et al [24], who in addition to detecting TNF- § , demonstrated IL-6 production by the plasma cells in chronic granulomatous skin conditions. In addition, Matthes and co-workers [8], were able to amplify TGF-g 1 mRNA from plasma cells isolated from human bone marrow and detected TGF-g 1 by ELISA from Ig-secreting cells in culture. TGF-g 1 is known to regulate ECM turnover, by down-regulating the synthesis and secretion of MMP and stimulating the production of TIMP [25].…”

Section: Discussionmentioning

confidence: 96%

“…Plasma cells are a prominent leukocyte found in tissues of patients with various chronic inflammatory disorders such as scleritis [4], rheumatoid arthritis (RA) [3,5], and Sjogren's syndrome [6]. Plasma cells have recently been identified as cytokine producing cells [7][8][9]. The expression of inflammatory mediators by plasma cells suggests that these cells may play an additional role in inflammation beyond antibody production.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of matrix metalloproteinases by human plasma cells and B lymphocytes

et al. 1998

View full text Add to dashboard Cite

Matrix metalloproteinases (MMP) are proteolytic enzymes that play a key role in tissue remodelling during physiological and pathological processes, by initiating the degradation of extracellular matrix. MMP overexpression can lead to tissue destruction which is characteristic of chronic inflammatory diseases such as rheumatoid arthritis and scleritis. Plasma cells are often abundant at such sites of chronic inflammation. In the present study we investigated whether plasma cells could contribute to matrix degradation by their expression of MMP In situ hybridization and immunohistochemical analyses on diseased synovial and scleral tissue demonstrated the expression of stromelysin-1 (MMP-3) and gelatinase B (MMP-9), but little or no tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) mRNA, by IgG-positive plasma cells. Northern blot analysis of RNA extracted from a human plasma cell line (ARH-77), Epstein-Barr virus-transformed B cells, and purified peripheral blood B cells, demonstrated expression of stromelysin mRNA. TIMP-1 mRNA was only detected by the more sensitive reverse transcription PCR method in these cell types. Plasma cells and B lymphocytes cultured in the presence of monensin demonstrated cytoplasmic gelatinase B. Gelatin and casein zymography on conditioned media (CM) derived from cytokine treated plasma cells revealed the induction of secreted gelatinase and stromelysin activity. Western blotting confirmed the presence of stromelysin-1 and TIMP-1 proteins in plasma cell CM. These data suggest that plasma cells are not only capable of modulating an inflammatory response by antibody and cytokine production, but also by their ability to produce MMP. Secretion of MMP from focal aggregates of plasma cells may play a critical role in tissue destructive diseases such as rheumatoid synovitis and scleritis.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Expression of matrix metalloproteinases by human plasma cells and B lymphocytes

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Plasma cells differentiate from B‐lymphocytes, produce immunoglobulins, and secrete cytokines such as TNF‐α, IL‐6, and TGF‐β113–16. Cytokines IL‐1α, IL‐1β, and IL‐6 are present in odontogenic jaw cyst fluids26, originating possibly from jaw cyst capsule plasma cells.…”

Section: Discussionmentioning

confidence: 99%

“…Plasma cells produce cytokines, tumour necrosis factor‐α (TNF‐α), interleukin‐6 (IL‐6), IL‐10, and transforming growth factor‐β (TGF‐β)13–16, which are capable of regulating MMPs at the transcriptional level5, 10, 11. Plasma cells can also express MMP‐9 (gelatinase‐B) and MMP‐3 (stromelysin‐1)17.…”

Section: Introductionmentioning

confidence: 99%

Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions

et al. 2001

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) collectively degrade extracellular matrix and basement membrane proteins in chronic inflammation and bone-destructive lesions. This study examined the ability of immunoglobulin-producing plasma cells, typically present in sites of chronic inflammation, to express collagenases (MMP-8 and -13) in vivo and in vitro. Phorbol-12-myristate-13-acetate, interleukin-6, and tumour necrosis factor-alpha and heparin with the tumour promoter or cytokines potently enhanced (up to nine-fold) MMP-8 and -13 expression by the RPMI 8226 myeloma cell line, as evidenced by western blotting and semi-quantitative reverse transcriptase-polymerase chain reaction. Immunohistochemical analysis and in situ hybridization revealed that plasma cells expressed MMP-8 and -13 focally in periapical granulomas, odontogenic cysts, and malignant plasmacytomas. MMP-8 and MMP-13 from plasma cells can participate in bone organic matrix destruction at sites of chronic inflammation and neoplastic growth. Since MMP-13 was more frequently expressed than MMP-8 in plasma cells of strongly recurring keratocysts and malignant plasmacytomas, it is concluded that plasma cell MMP-13 has a particularly important role in benign and malignant bone-destructive lesions.

show abstract

“…The mechanism underlying this unexpected outcome is speculative. It suggests an ameliorative effect of mature B cells and/ or plasma cells on MS disease activity, possibly via secretion of immunomodulatory or neuroprotective antibodies [24,25,66] or cytokines, such as IL-10 and TGFβ [67,68]. …”

Section: Emerging Therapiesmentioning

confidence: 99%

B-Cell Targeting Agents in the Treatment of Multiple Sclerosis

Braley

Segal

2013

Curr Treat Options Neurol

View full text Add to dashboard Cite

Opinion statement The aims of this article are to discuss the potential role of B lymphocytes in the pathogenesis of multiple sclerosis (MS) and in the mechanisms of action of approved and emerging disease modifying therapies. Over the last few years, significant progress has been made in the introduction of novel pharmacologic treatments that reduce the frequency of clinical exacerbations and radiological lesion formation in relapsing remitting MS. The mechanism of action of a number of these disease modifying therapies (DMT) implicates B cells in the pathogenesis, as well as in the regulation, of MS. Recent advances in MS therapeutics indicate that B lymphocytes can act as critical mediators, as well as regulators, of disease activity in MS. Further research into B-cell subset trafficking patterns, functional activities and interactions with other immune cells in the context of neuroinflammation is likely to inform the development of future generations of DMT.

show abstract

Cytokine expression and regulation of human plasma cells: disappearance of interleukin‐10 and persistence of transforming growth factor‐β₁

Cited by 22 publications

References 26 publications

Expression of matrix metalloproteinases by human plasma cells and B lymphocytes

Expression of matrix metalloproteinases by human plasma cells and B lymphocytes

Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions

B-Cell Targeting Agents in the Treatment of Multiple Sclerosis

Contact Info

Product

Resources

About

Cytokine expression and regulation of human plasma cells: disappearance of interleukin‐10 and persistence of transforming growth factor‐β1

Cited by 22 publications

References 26 publications

Expression of matrix metalloproteinases by human plasma cells and B lymphocytes

Expression of matrix metalloproteinases by human plasma cells and B lymphocytes

Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions

B-Cell Targeting Agents in the Treatment of Multiple Sclerosis

Contact Info

Product

Resources

About

Cytokine expression and regulation of human plasma cells: disappearance of interleukin‐10 and persistence of transforming growth factor‐β₁